Subhadip Hajra

Dr. Subhadip Hajra


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
RGRITUPARNA GHOSH
RITUPARNA GHOSH
PSPriya Samanta
Priya Samanta
RSRupali Sarkar
Rupali Sarkar
SBSouradeep Biswas
Souradeep Biswas
PSprosenjit saha
prosenjit saha
ABArijit Bhowmik
Arijit Bhowmik
Advancement in novel target detection using improved molecular cancer biology has opened up new avenues for promising anti-cancer drug development. In the past two decades, the mechanism of tumor hypoxia has become more understandable with the discovery of hypoxia-inducible factor-1α (HIF-1α). It is a major transcriptional regulator that coordinates the activity of various transcription factors and their downstream molecules involved in tumorigenesis. HIF-1α not only plays a crucial role in the adaptation of tumor cells to hypoxia but also regulates different biological processes, including cell proliferation, survival, cellular metabolism, angiogenesis, metastasis, cancer stem cell maintenance, and propagation. Therefore, HIF-1α overexpression is strongly associated with poor prognosis in patients with different solid cancers. Hence, pharmacological targeting of HIF-1α has been considered to be a novel cancer therapeutic strategy in recent years. In this review, we provide brief descriptions of natural and synthetic compounds as HIF-1α inhibitors that have the potential to accelerate anticancer drug discovery. This review also introduces the mode of action of these compounds for a better understanding of the chemical leads, which could be useful as cancer therapeutics in the future.

23 March 2023 in Stem Cell Reviews and Reports
Verified
Journal Article
Closed access
PDF file
PSPriya Samanta
Priya Samanta
ABArijit Bhowmik
Arijit Bhowmik
SBSouradeep Biswas
Souradeep Biswas
RSRupali Sarkar
Rupali Sarkar
RGRituparna Ghosh
Rituparna Ghosh
SHSubhadip Hajra
Subhadip Hajra

26 September 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
PSPriya Samanta
Priya Samanta
RGRituparna Ghosh
Rituparna Ghosh
SPShampa Pakhira
Shampa Pakhira
MMMrinmoyee Mondal
Mrinmoyee Mondal
SBSouradeep Biswas
Souradeep Biswas
SHSubhadip Hajra
Subhadip Hajra

14 May 2024 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
MCMohona Chakravarti
Mohona Chakravarti
SBSaurav Bera
Saurav Bera
SDSukanya Dhar
Sukanya Dhar
ASAnirban Sarkar
Anirban Sarkar
PCPritha Roy Choudhury
Pritha Roy Choudhury
ABAnamika Bose
Anamika Bose
Targeting exhausted CD8+ T-cell (TEX)–induced aggravated cancer stem cells (CSC) holds immense therapeutic potential. In this regard, immunomodulation via Neem Leaf Glycoprotein (NLGP), a plant-derived glycoprotein immunomodulator is explored. Since former reports have proven immune dependent–tumor restriction of NLGP across multiple tumor models, we hypothesized that NLGP might reprogram and rectify TEX to target CSCs successfully. In this study, we report that NLGP’s therapeutic administration significantly reduced TEX-associated CSC virulence in in vivo B16-F10 melanoma tumor model. A similar trend was observed in in vitro generated TEX and B16-F10/MCF7 coculture setups. NLGP rewired CSCs by downregulating clonogenicity, multidrug resistance phenotypes and PDL1, OCT4, and SOX2 expression. Cell cycle analysis revealed that NLGP educated–TEX efficiently pushed CSCs out of quiescent phase (G0G1) into synthesis phase (S), supported by hyper-phosphorylation of G0G1–S transitory cyclins and Rb proteins. This rendered quiescent CSCs susceptible to S-phase–targeting chemotherapeutic drugs like 5-fluorouracil (5FU). Consequently, combinatorial treatment of NLGP and 5FU brought optimal CSC-targeting efficiency with an increase in apoptotic bodies and proapoptotic BID expression. Notably a strong nephron-protective effect of NLGP was also observed, which prevented 5FU-associated toxicity. Furthermore, Dectin-1–mediated NLGP uptake and subsequent alteration of Notch1 and mTOR axis were deciphered as the involved signaling network. This observation unveiled Dectin-1 as a potent immunotherapeutic drug target to counter T-cell exhaustion. Cumulatively, NLGP immunotherapy alleviated exhausted CD8+ T-cell-induced CSC aggravation. Implications: Our study recommends that NLGP immunotherapy can be utilized to counter ramifications of T-cell exhaustion and to target therapy elusive aggressive CSCs without evoking toxicity.

7 December 2023 in Journal of Traditional Chinese Medical Sciences
Verified
Journal Article
Open access
APAmrita Pal
Amrita Pal
RRRibhu Ray
Ribhu Ray
ACAnirban Chouni
Anirban Chouni
SHSubhadip Hajra
Subhadip Hajra
SPSantanu Paul
Santanu Paul

17 June 2026
Verified
Other
Open access
MCMohona Chakravarti
Mohona Chakravarti
SBSaurav Bera
Saurav Bera
SDSukanya Dhar
Sukanya Dhar
ASAnirban Sarkar
Anirban Sarkar
PCPritha Roy Choudhury
Pritha Roy Choudhury
ABAnamika Bose
Anamika Bose
The file contains Supplementary Figure S2